Switching to Raltegravir From a Virologically Effective Boosted Protease Inhibitor Regimen: A Comparative Effectiveness Analysis From the French Hospital Database on HIV (FHDH-ANRS CO4).

about

Switching to Raltegravir From a Virologically Effective Boosted Protease Inhibitor Regimen: A Comparative Effectiveness Analysis From the French Hospital Database on HIV (FHDH-ANRS CO4).

Item

http://www.wikidata.org/entity/Q38406037

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Switching to Raltegravir From ...... tabase on HIV (FHDH-ANRS CO4).

@en

type

Item

label

Switching to Raltegravir From ...... tabase on HIV (FHDH-ANRS CO4).

@en

prefLabel

Switching to Raltegravir From ...... tabase on HIV (FHDH-ANRS CO4).

@en

P1476

Switching to Raltegravir From ...... tabase on HIV (FHDH-ANRS CO4).

@en

P2093

Anne Simon

http://www.w3.org/2001/XMLSchema#string

French Hospital Database on HIV (FHDH-ANRS CO4)

http://www.w3.org/2001/XMLSchema#string

Jean-Marc Lacombe

http://www.w3.org/2001/XMLSchema#string

Valérie Potard

http://www.w3.org/2001/XMLSchema#string

P2860

Marginal structural models and causal inference in epidemiology

Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study.

Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies.

Raltegravir Pharmacokinetics in Patients on Asunaprevir-Daclatasvir

Average adherence to boosted protease inhibitor therapy, rather than the pattern of missed doses, as a predictor of HIV RNA replication.

Raltegravir has a low propensity to cause clinical drug interactions through inhibition of major drug transporters: an in vitro evaluation.

Significant reduction in HIV virologic failure during a 15-year period in a setting with free healthcare access.

Raltegravir plus two nucleoside analogues as combination antiretroviral therapy in HIV-infected patients who require cancer chemotherapy.

Cohort Profile: French hospital database on HIV (FHDH-ANRS CO4).

Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events

P304

1254-1261

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/CID/CIW498

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Dominique Costagliola

Jean-Jacques Parienti

P577

2016-08-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27543648

http://www.w3.org/2001/XMLSchema#string

P921

virology